Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial

Background Nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro . However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods In a multicentre, randomised, double-blind, placebo-controlled trial, adu... View More